Glucokinase diabetes in children

Czech version

Authors: Woznicová Kateřina ¹; Strnadel Jiří ¹; Průhová Štěpánka ²; Pavlíček Jan ^1,3; Hladík Michal ^1,3
Authors‘ workplace: Klinika dětského lékařství, FN Ostrava ¹; Pediatrická klinika 2. LF UK, a FN Motol, Praha ²; Lékařská fakulta, Ostravská univerzita, Ostrava ³
Published in: Čes-slov Pediat 2022; 77 (2): 86-90.
Category: Case Report

Overview

Glucokinase diabetes is a form of monogenic diabetes, caused by a heterozygous pathogenic variant in the GCK gene, which encodes the enzyme glucokinase. It is a part of MODY (Maturity Onset Diabetes of the Young) diabetes, which is a heterogeneous group of disorders whose overall prevalence is estimated to 2-3 % of the European diabetic population with manifestation of diabetes until 30 years of age. The clinical features include typically an autosomal dominant inheritance and young age of onset (usually first occurs in adolescence or early adulthood). Glucokinase diabetes is one the most common MODY subtypes, accounting for 65 % of patients with MODY in the Czech Republic. Being diagnosed in adolescents and young adults, it may lead to identifying other cases in family members. A chronic mild hyperglycemia is typical for otherwise asymptomatic patients. Most of these cases do not require any treatment. In the case report we present a case of a randomly found hyperglycemia in an 8-year-old female with short stature. After a series of medical tests, a pathogenic variant in the GCK gene was identified.

Keywords:

hyperglycemia – GCK – Maturity Onset Diabetes of the Young

Sources

1. Lebl J, Al Taji E, Koloušková S, et al. Dětská endokrinologie a diabetologie. Praha: Galén 2016: 372–382.

2. Cammidge PJ. Diabetes Mellitus and Heredity. BMJ 1928; 2: 738-41.

3. Tattersall RB. Mild familial diabetes of the young: a clinical history. Diabet Med 1998; 15: 1–4.

4. Fajans SS, Bell GI. MODY : history, genetics, pathophysiology, and clinical decision making. Diabetes Care 2011; 34(8): 1878–84.

5. Hattersley, AT . Maturity-onset diabetes of the young: clinical heterogenity explained by genetic heterogenity. Diabet Med 1998; 15: 15–24.

6. Stanik J, Dusatkova P, Cinek O, et al. De novo mutations of GCK, HNF1A and HNF4A may be more frequent in MODY than previously assumed. Diabetologia 2014; 57(3): 480–4.

7. Ellard S, Bellanné-Chantelot C, Hattersley AT . Best practice guidelines fot the molecular genetic diagnosis of maturity-onset diabetes of the young, Diabetologia 2008; 51: 546–553.

8. Shepherd M. Our evolving understanding of monogenetic diabetes: possibilities of improving glycaemic control following transfer from insulin to sulphonylureas. Prim Care Diabetes 2008; 2(2): 87–90.

9. Heuvel-Borsboom H, de Valk HW, Losekoot M, et al. Maturity onset diabetes of the young: Seek and you will find. Neth J Med 2016; 70(5): 193–200.

10. Fajans SS, Bell Gl, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001; 345(13): 971–980.

11. Sanyoura M, Phillipson LH, Naylor R. Monogenetic diabetes in children and adolescents: Recognition and treatment options. Current Diabetes Rep 2018; 18(8): 1–13.

12. Urakami T. Maturity-onset diabetes of the young (MODY ): current perspectives on diagnosis and treatment. Diabetes, metabolic syndrome and obesity: targets and therapy 2019; 12: 1047–1056.

13. Průhová Š, Lebl J. Kapitola z knihy: Trendy soudobé diabetologie. Svazek 11. Praha: Galén 2007.

14. Průhová Š, Dušatková P, Šumník Z, et al. Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations. Pediatr Diabetes 2010; 11: 529–35.

15. Průhová Š, Ek J, Lebl J, et al. Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4A, GCK and HNF-1A. Diabetologia 2003; 46: 291–295.

16. Feigerlová E, Průhová Š, Dittertová L, et al. Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents. Eur J Pediatr 2006; 165: 446–452.

17. Matschinski FM, Glaser B, Magnuson MA. Pancreatic β-cellglcokinase: closingthe gap between theoretical concepts and experimental realities. Diabetes 1998; 47: 307–315.

18. Nolan CJ, Prentki M. The islet β-cell: fuel responsive and vulnerable. Trends Endocrinol Metab 2008; 19: 285–291.

19. Velho G, Froguel P, Clement K, et al. Primary pancreatic β-cell secretory defect caused by mutation in glucokinase gene in kindreds of maturity onset diabetes of the young. Lancet 1992; 340: 444–448.

20. Byrne MM, Sturis J, Fajans SS, et al. Altered insulin secretory responses to glucose in subjects with a mutation in the MODY 1 geneon chromosome 20. Diabetes 1995; 44: 699– 704.

21. Gloyn AL. Glucokinase (GCK)mutation in hyper- and hypoglycaemia: maturity-onset diabetes og the young, permanent neonatal diabetes, and hyperinsulinemia in infancy. Human Mutat 2003; 22: 353–362.

22. Steele AM, Shields BM, Wensley KJ, et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycaemia. JAMA 2014; 311(3): 279–86.

23. Velho G, Blanché H, Vaxillaire M, et al. Identification od 14 new glucokinase mutations and description og the clinical profile of 42 MODY -2 families, Diabetologia 1997; 40(2): 217–24.

24. Hattersley AT . Molecular genetics goes to the diabetes clinic. Clin Med 2005; 5(5): 476–81.

25. Hattersley AT , Bruining J, Shield J, at al. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenetic diabetes in children. Pediat Diab 2006; 7: 352–360.

26. Velho G, Hattersley AT , Froguel P. Maternal diabetes alters birth weight in glucokinase-deficient (MODY 2) kindreds but has no influence on adult weight, height, insulin secretion or insulin sensitivity. Diabetologia 2000; 43: 1060–1063.

27. Richards S, Aziz N, Bale S, et al. Committee ALQA. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17(5): 405–424.

28. Šumník Z, Venháčová J, Škvor J, et al.; ČENDA Project Group. Five years of improving diabetes control in Czech children after the establishment of the population-based childhood diabetes register ČENDA. Pediatr Diabetes 2020; 21(1): 77–87.

29. Dusatkova P, Pruhova S, Borowiec M, et al. Ancestral mutations may cause a significant proportion of GCK-MODY . Pediatr Diabetes 2012; 13(6): 489–98.

30. Pruhova S, Dusatkova P, Sumnik Z, et al. Glucokinase diabetes in 103 families from a country-based study in the Czech Republic: geographically restricted distribution of two prevalent GCK mutations. Pediatr Diabetes 2010; 11(8): 529–35.